Drugs / SBS-101
last change May 2023 re-read 3 minutes ago

SBS-101

Developed for
oral mucosa leukoplakia
Investigated by
Skyline Biosciences

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03939364 Jan 2022 → Apr 2023 oral mucosa leukoplakia Skyline Biosciences Withdrawn No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SBS-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939364 ↗